Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predispositionKriege, M., Brekelmans, CTM., Boetes, C., Besnard, PE., Zonderland, HM., Obdeijn, IM., Manoliu, RA., Kok, T., Peterse, H., Tilanus-Linthorst, MMA., Muller, SH., Meijer, S., Oosterwijk, JC., Beex, LVAM., Tollenaar, RAEM., de Koning, HJ., Rutgers, EJT., Klijn, JGM. & Magnetic Resonance Imaging Screeni, 29-Jul-2004, In : New England Journal of Medicine. 351, 5, p. 427-437 11 p.
Research output: Contribution to journal › Article › Academic › peer-review
The value of regular surveillance for breast cancer in women with a genetic or familial predisposition to breast cancer is currently unproven. We compared the efficacy of magnetic resonance imaging (MRI) with that of mammography for screening in this group of high-risk women.
Women who had a cumulative lifetime risk of breast cancer of 15 percent or more were screened every six months with a clinical breast examination and once a year by mammography and MRI, with independent readings. The characteristics of the cancers that were detected were compared with the characteristics of those in two different age-matched control groups.
We screened 1909 eligible women, including 358 carriers of germ-line mutations. Within a median follow-up period of 2.9 years, 51 tumors (44 invasive cancers, 6 ductal carcinomas in situ, and 1 lymphoma) and 1 lobular carcinoma in situ were detected. The sensitivity of clinical breast examination, mammography, and MRI for detecting invasive breast cancer was 17.9 percent, 33.3 percent, and 79.5 percent, respectively, and the specificity was 98.1 percent, 95.0 percent, and 89.8 percent, respectively. The overall discriminating capacity of MRI was significantly better than that of mammography (P
MRI appears to be more sensitive than mammography in detecting tumors in women with an inherited susceptibility to breast cancer.
|Number of pages||11|
|Journal||New England Journal of Medicine|
|Publication status||Published - 29-Jul-2004|
- MUTATION CARRIERS, BRCA2 MUTATION, HIGH-RISK, HISTORY, TRIALS, SURVEILLANCE, OOPHORECTOMY, MASTECTOMY, MORTALITY, DENSITY